亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses

骨质疏松症 医学 内科学
作者
Ryoji Tominaga,Tatsuyoshi Ikenoue,Ryosuke Ishii,Kakuya Niihata,Tetsuro Aita,T. Okuda,Sayaka Shimizu,Masataka Taguri,Noriaki Kurita
出处
期刊:Journal of Bone and Mineral Research [Oxford University Press]
被引量:4
标识
DOI:10.1093/jbmr/zjaf010
摘要

Abstract This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period. Cardiovascular disease (myocardial infarction or stroke) was identified based on information regarding diagnosis, medical procedures, and drug codes. Facility-level prescription preference for romosozumab was used as an instrumental variable, defined as the proportion of romosozumab prescribed at the patient’s facility within 90 days prior to the index date. Of the 59 694 included prescriptions, 8808 were for romosozumab and 50 886 were for bisphosphonates. The mean age in the romosozumab group was higher than that in the bisphosphonates group (80.5 vs. 78.2 years, respectively), and most patients were females (85.3 vs. 80.2%, respectively). The incidence of cardiovascular disease within 1 year of prescription was 12.3 per 100 person-years for romosozumab versus 11.4 for bisphosphonates (unadjusted incidence rate ratio: 1.08, 95% confidence interval: 1.00–1.18). An instrumental variable analysis using the two-stage residual inclusion method yielded a hazard ratio of 1.30 (95% confidence interval: 0.88–1.90) for romosozumab compared with bisphosphonates over 1 year. Although possibly underpowered, this study showed that no definitive evidence of increased cardiovascular risk associated with romosozumab use compared with bisphosphonates was observed in patients with osteoporosis. These findings should be further validated by larger pharmacoepidemiological studies to alleviate clinicians’ concerns about romosozumab’s safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
和谐寻云完成签到,获得积分10
刚刚
14秒前
无极微光的应助被生气来找我采纳,获得20
16秒前
车访枫完成签到,获得积分10
21秒前
阔达的沛岚完成签到,获得积分10
25秒前
称心的忆山完成签到,获得积分10
29秒前
33秒前
40秒前
儒雅的白筠完成签到,获得积分10
1分钟前
1分钟前
1分钟前
yang1316发布了新的文献求助10
1分钟前
科研通AI6.2的应助被anya采纳,获得100
1分钟前
madeleinli的应助被科研通管家采纳,获得20
1分钟前
SciGPT的应助被yang1316采纳,获得30
1分钟前
秀丽的紫山完成签到,获得积分10
1分钟前
吉吉急急急完成签到 ,获得积分10
1分钟前
1分钟前
研友_VZG7GZ的应助被zoomer采纳,获得10
1分钟前
大气的夜雪完成签到,获得积分10
1分钟前
1分钟前
阳光幻巧完成签到,获得积分10
1分钟前
闪闪灵雁发布了新的文献求助10
1分钟前
2分钟前
2分钟前
悦耳的半兰完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
zoomer发布了新的文献求助10
2分钟前
2分钟前
2分钟前
anya发布了新的文献求助100
2分钟前
2分钟前
zoomer完成签到,获得积分10
2分钟前
所所的应助被SUNny采纳,获得10
2分钟前
2分钟前
丰富的雅绿完成签到,获得积分10
2分钟前
犹豫友卉完成签到,获得积分10
2分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179889
求助须知:如何正确求助?哪些是违规求助? 9570071
关于积分的说明 21808307
捐赠科研通 7775662
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557328
邀请新用户注册赠送积分活动 2478864